Brand Names for E. coli UTI Treatment
The question asks about "brand names," but antibiotic selection for E. coli urinary tract infections should be based on generic drug names and local resistance patterns, not brand names 1. Guidelines universally recommend specific antimicrobial agents by their generic names, as brand names vary by country and manufacturer.
First-Line Treatment Options
For uncomplicated cystitis in women, the recommended first-line agents are:
- Fosfomycin trometamol (3g single dose) - highly effective with excellent activity against both ESBL and non-ESBL E. coli 1, 2
- Nitrofurantoin (50-100mg four times daily or 100mg twice daily for 5 days) - maintains ~97% susceptibility against E. coli 1, 2
- Pivmecillinam (400mg three times daily for 3-5 days) 1
These agents demonstrate 100% activity against both ESBL-producing and non-ESBL E. coli strains 2.
Alternative Options
When first-line agents cannot be used:
- Cephalosporins (e.g., cefadroxil 500mg twice daily for 3 days) - only if local E. coli resistance is <20% 1
- Trimethoprim-sulfamethoxazole (160/800mg twice daily for 3-5 days) - but high resistance rates in many communities preclude empiric use 1, 3
- Fluoroquinolones (ciprofloxacin, levofloxacin) - only if local resistance <10% 1
For Complicated UTIs or Pyelonephritis
Empirical treatment requires broader coverage:
- Amoxicillin plus aminoglycoside
- Second-generation cephalosporin plus aminoglycoside
- Intravenous third-generation cephalosporin 1
Treatment duration is typically 7-14 days for complicated infections 1.
Critical Considerations
The rise of ESBL-producing E. coli (38-51% prevalence in some regions) severely limits treatment options 2. For ESBL infections, carbapenems, piperacillin-tazobactam, fosfomycin, nitrofurantoin, and pivmecillinam remain effective 2, 3.
Avoid fluoroquinolones empirically if:
- Patient recently used fluoroquinolones (within 6 months)
- Patient from urology department
- Local resistance exceeds 10% 1
The specific brand name used will depend entirely on which generic formulation is available in your region and healthcare system.